ACADIA Pharmaceuticals Inc.
ACAD
$25.33
$0.803.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 222.16M | 228.88M | 226.45M | 128.51M | 30.57M |
| Total Depreciation and Amortization | 13.67M | 13.31M | 15.88M | 12.31M | 11.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.40M | -92.47M | -88.77M | 66.36M | 57.99M |
| Change in Net Operating Assets | 45.47M | -756.00K | 4.16M | -4.44M | -19.49M |
| Cash from Operations | 187.91M | 148.96M | 157.72M | 202.73M | 80.53M |
| Capital Expenditure | -820.00K | -523.00K | -523.00K | -70.00K | -50.00K |
| Sale of Property, Plant, and Equipment | 146.52M | 146.52M | 146.52M | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -273.35M | -286.54M | -176.53M | -152.97M | -36.42M |
| Cash from Investing | -127.65M | -140.55M | -30.54M | -153.04M | -36.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.03M | 7.64M | 6.85M | 10.31M | 22.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20.03M | 7.64M | 6.85M | 10.31M | 22.79M |
| Foreign Exchange rate Adjustments | -83.00K | -104.00K | -94.00K | -46.00K | -8.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.20M | 15.95M | 133.93M | 59.96M | 66.84M |